Devon Livingston-Rosanoff1, Jessica Schumacher2, Kara Vande Walle3, Trista Stankowski-Drengler3, Caprice C Greenberg3, Heather Neuman3, Lee G Wilke4. 1. Division of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI; Wisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI. Electronic address: livingstonrosanoff@surgery.wisc.edu. 2. Wisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI. 3. Division of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI; Wisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI. 4. Division of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI.
Abstract
BACKGROUND: Tumor size has historically been used to stage breast cancer and guide treatment recommendations. The importance of tumor biology in long-term outcomes is increasingly being acknowledged. No large studies have examined the relative roles of tumor size and receptor status on response to neoadjuvant chemotherapy (NAC) in breast cancer. PATIENTS AND METHODS: The National Cancer Database was queried for women who underwent NAC and surgery for unilateral clinical stage I to III (cT1-3) invasive breast cancer from 2010 to 2013. Multivariable logistic regression models were used to assess the relation between receptor status, tumor size, and pathologic complete response (pCR) while controlling for other biologic, sociodemographic, diagnosis, and treatment factors. RESULTS: We included 38,864 women in this study, most presented with cT2 disease (55%). Patients predominantly had estrogen receptor (ER)/progesterone receptor (PR)-positive (ER/PR+) HER2- (45%) or ER/PR- HER2- (28%) disease. Nineteen percent (7432 patients) had a pCR. cT3 (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.59-0.70) but not cT2 cancers (OR, 0.95; 95% CI, 0.89-1.02) were associated with lower pCR rates compared with cT1 disease. HER2+ (ER/PR+ HER2+: OR, 2.94; 95% CI, 2.72-3.18; ER/PR- HER2+: OR, 6.45; 95% CI, 5.92-7.02) and ER/PR- HER2- cancers (OR, 3.94; 95% CI, 3.68-4.22) were more likely to experience pCR than those with ER/PR+ HER2- cancers. Receptor status was more strongly associated with pCR than tumor size. CONCLUSION: Tumor size is independently associated with pCR after NAC after controlling for receptor status, although the effect of receptor status is stronger. These data reinforce the importance of receptor status as well as tumor size, each of which might act as surrogates for tumor biology, in setting expectations for outcomes in patients who undergo NAC.
BACKGROUND:Tumor size has historically been used to stage breast cancer and guide treatment recommendations. The importance of tumor biology in long-term outcomes is increasingly being acknowledged. No large studies have examined the relative roles of tumor size and receptor status on response to neoadjuvant chemotherapy (NAC) in breast cancer. PATIENTS AND METHODS: The National Cancer Database was queried for women who underwent NAC and surgery for unilateral clinical stage I to III (cT1-3) invasive breast cancer from 2010 to 2013. Multivariable logistic regression models were used to assess the relation between receptor status, tumor size, and pathologic complete response (pCR) while controlling for other biologic, sociodemographic, diagnosis, and treatment factors. RESULTS: We included 38,864 women in this study, most presented with cT2 disease (55%). Patients predominantly had estrogen receptor (ER)/progesterone receptor (PR)-positive (ER/PR+) HER2- (45%) or ER/PR- HER2- (28%) disease. Nineteen percent (7432 patients) had a pCR. cT3 (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.59-0.70) but not cT2cancers (OR, 0.95; 95% CI, 0.89-1.02) were associated with lower pCR rates compared with cT1 disease. HER2+ (ER/PR+ HER2+: OR, 2.94; 95% CI, 2.72-3.18; ER/PR- HER2+: OR, 6.45; 95% CI, 5.92-7.02) and ER/PR- HER2- cancers (OR, 3.94; 95% CI, 3.68-4.22) were more likely to experience pCR than those with ER/PR+ HER2- cancers. Receptor status was more strongly associated with pCR than tumor size. CONCLUSION:Tumor size is independently associated with pCR after NAC after controlling for receptor status, although the effect of receptor status is stronger. These data reinforce the importance of receptor status as well as tumor size, each of which might act as surrogates for tumor biology, in setting expectations for outcomes in patients who undergo NAC.
Authors: Nehmat Houssami; Petra Macaskill; Gunter von Minckwitz; Michael L Marinovich; Eleftherios Mamounas Journal: Eur J Cancer Date: 2012-07-03 Impact factor: 9.162
Authors: François-Clément Bidard; Stefan Michiels; Sabine Riethdorf; Volkmar Mueller; Laura J Esserman; Anthony Lucci; Bjørn Naume; Jun Horiguchi; Rafael Gisbert-Criado; Stefan Sleijfer; Masakazu Toi; Jose A Garcia-Saenz; Andreas Hartkopf; Daniele Generali; Françoise Rothé; Jeffrey Smerage; Laura Muinelo-Romay; Justin Stebbing; Patrice Viens; Mark Jesus M Magbanua; Carolyn S Hall; Olav Engebraaten; Daisuke Takata; José Vidal-Martínez; Wendy Onstenk; Noriyoshi Fujisawa; Eduardo Diaz-Rubio; Florin-Andrei Taran; Maria Rosa Cappelletti; Michail Ignatiadis; Charlotte Proudhon; Denise M Wolf; Jessica B Bauldry; Elin Borgen; Rin Nagaoka; Vicente Carañana; Jaco Kraan; Marisa Maestro; Sara Yvonne Brucker; Karsten Weber; Fabien Reyal; Dominic Amara; Mandar G Karhade; Randi R Mathiesen; Hideaki Tokiniwa; Antonio Llombart-Cussac; Alessandra Meddis; Paul Blanche; Koenraad d'Hollander; Paul Cottu; John W Park; Sibylle Loibl; Aurélien Latouche; Jean-Yves Pierga; Klaus Pantel Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Won Hwa Kim; Hye Jung Kim; Ho Yong Park; Ji Young Park; Yee Soo Chae; So Mi Lee; Seung Hyun Cho; Kyung Min Shin; Sang Yub Lee Journal: Ultrasound Med Biol Date: 2018-12-17 Impact factor: 2.998
Authors: Caprice C Greenberg; Stuart R Lipsitz; Melissa E Hughes; Stephen B Edge; Richard Theriault; John L Wilson; W Bradford Carter; Douglas W Blayney; Joyce Niland; Jane C Weeks Journal: Ann Surg Date: 2011-08 Impact factor: 12.969